Dr. Grossniklaus was appointed Interim Vice Chair of Emory Eye Center on March 14, 2016.  He is the senior professor of Ophthalmology, Department of Ophthalmology, Emory University School of Medicine. He is founding director of the Ocular Oncology and Pathology service and director of the L.F. Montgomery Laboratory and is board certified in both ophthalmology and anatomic pathology. He has expertise in diagnostic ophthalmic pathology, ocular oncology and ophthalmic pathology research, including drug delivery. In 2012, under his directorship, the Montgomery Lab reached an accumulated 65,000 specimens evaluated since the 1940s, with Grossniklaus having signed out over 50,000 cases himself. Dr. Grossniklaus has over 500 publications in peer reviewed journals. He has written/co-written 25 book chapters and edited/co-edited 10 books/monographs. Diagnostic ophthalmic pathology includes surgical pathology of ocular and periocular tissue, including cornea, vitreous, retina, uvea, conjunctiva, eyelid, and orbit. Ocular oncology includes conjunctival, retinal, iris, ciliary body and choroidal tumors. He has expertise in translational research, having served as the director of the Submacular Surgery Trials (SST) Pathology Center and a clinical trial to treat patients with uveal melanoma. His clinical areas of interest are ocular oncology and ophthalmic pathology. His research areas of interest are treatment of primary ocular melanoma and retinoblastoma, molecular pathology of retinoblastoma, and control of metastatic melanoma from the eye to the liver. Dr. Grossniklaus regularly see patients with ocular malignancies, and he treats them with surgery, lasers and radiation therapy. Dr. Grossniklaus was appointed Interim Vice Chair of Emory Eye Center on March 14, 2016.  He is the senior professor of Ophthalmology, Department of Ophthalmology, Emory University School of Medicine. He is founding director of the Ocular Oncology and Pathology service and director of the L.F. Montgomery Laboratory and is board certified in both ophthalmology and anatomic pathology. He has expertise in diagnostic ophthalmic pathology, ocular oncology and ophthalmic pathology research, including drug delivery. In 2012, under his directorship, the Montgomery Lab reached an accumulated 65,000 specimens evaluated since the 1940s, with Grossniklaus having signed out over 50,000 cases himself. Dr. Grossniklaus has over 500 publications in peer reviewed journals. He has written/co-written 25 book chapters and edited/co-edited 10 books/monographs. Diagnostic ophthalmic pathology includes surgical pathology of ocular and periocular tissue, including cornea, vitreous, retina, uvea, conjunctiva, eyelid, and orbit. Ocular oncology includes conjunctival, retinal, iris, ciliary body and choroidal tumors. He has expertise in translational research, having served as the director of the Submacular Surgery Trials (SST) Pathology Center and a clinical trial to treat patients with uveal melanoma. His clinical areas of interest are ocular oncology and ophthalmic pathology. His research areas of interest are treatment of primary ocular melanoma and retinoblastoma, molecular pathology of retinoblastoma, and control of metastatic melanoma from the eye to the liver. Dr. Grossniklaus regularly see patients with ocular malignancies, and he treats them with surgery, lasers and radiation therapy.

• Medical and surgical management of glaucoma • Laser therapy  • Surgical management of cataracts